The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.

The FDA said the popular weight-loss drug should be combined with a reduced ... is marketed as Zepbound for weight loss and Mounjaro as a diabetes treatment. Zepbound's side effects can include ...

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in ... or exceeding demand and that, based on our best judgment, it will meet or exceed projected ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage ... to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources ...